Loading
A phase 3 trial of MRG003, Pucotenlimab, Gemcitabine in nasopharyngeal carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT06976190 by Lepu Biopharma Co., Ltd., with 446 participants planned, started 2025-05-06 and due to reach its primary completion in 2029-05. Interventions recorded: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MRG003, Lepu Biopharma, Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Lepu Biopharma, Pucotenlimab, Immune checkpoint inhibitors.
Shares MRG003, Lepu Biopharma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Docetaxel, Gemcitabine.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Gemcitabine, Immune checkpoint inhibitors.
Shares Lepu Biopharma, Pucotenlimab.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/